Header Logo

Connection

NICOLA HANANIA to Treatment Outcome

Back to Details
This is a "connection" page, showing publications NICOLA HANANIA has written about Treatment Outcome.
NICOLA HANANIA
Connection Strength
1.947
Treatment Outcome
  1. Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils. Eur Respir Rev. 2025 Oct; 34(178).
    View in: PubMed
    Score: 0.080
  2. Comparative effectiveness of inhaled fluticasone propionate/salmeterol and budesonide/formoterol fixed-dose combinations in asthma control - a retrospective United States database analysis. Respir Med. 2025 Aug-Sep; 245:108172.
    View in: PubMed
    Score: 0.077
  3. Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab. J Allergy Clin Immunol Pract. 2024 02; 12(2):512-514.e2.
    View in: PubMed
    Score: 0.069
  4. The effectiveness of pulmonary rehabilitation on chronic obstructive pulmonary disease patients with concurrent presence of comorbid depression and anxiety. Respir Med. 2022 06; 197:106850.
    View in: PubMed
    Score: 0.062
  5. Predictors of premature discontinuation and prevalence of dropouts from a pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease. Respir Med. 2022 03; 193:106742.
    View in: PubMed
    Score: 0.061
  6. Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA. J Allergy Clin Immunol Pract. 2022 01; 10(1):222-228.
    View in: PubMed
    Score: 0.059
  7. Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials. Int J Chron Obstruct Pulmon Dis. 2021; 16:1925-1938.
    View in: PubMed
    Score: 0.059
  8. Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. Int J Chron Obstruct Pulmon Dis. 2021; 16:865-875.
    View in: PubMed
    Score: 0.058
  9. Determinants of lung function improvement with omalizumab in adults with allergic asthma. J Allergy Clin Immunol Pract. 2020 06; 8(6):2068-2070.
    View in: PubMed
    Score: 0.053
  10. Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions. Int J Chron Obstruct Pulmon Dis. 2019; 14:1127-1138.
    View in: PubMed
    Score: 0.051
  11. Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:1045-1051.
    View in: PubMed
    Score: 0.051
  12. Validity and Responsiveness of the?Depression Anxiety Stress Scales-21?(DASS-21) in?COPD. Chest. 2019 06; 155(6):1166-1177.
    View in: PubMed
    Score: 0.049
  13. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:117-127.
    View in: PubMed
    Score: 0.049
  14. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019 04; 143(4):1629-1633.e2.
    View in: PubMed
    Score: 0.049
  15. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. Int J Chron Obstruct Pulmon Dis. 2018; 13:499-508.
    View in: PubMed
    Score: 0.046
  16. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018 02; 73(2):490-497.
    View in: PubMed
    Score: 0.045
  17. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017 05; 126:105-115.
    View in: PubMed
    Score: 0.044
  18. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 10; 4(10):781-796.
    View in: PubMed
    Score: 0.042
  19. The Responsiveness of the Anxiety Inventory for Respiratory Disease Scale Following Pulmonary Rehabilitation. Chest. 2016 07; 150(1):188-95.
    View in: PubMed
    Score: 0.041
  20. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug; 70(8):748-56.
    View in: PubMed
    Score: 0.038
  21. Role of anticholinergics in asthma management: recent evidence and future needs. Curr Opin Pulm Med. 2015 Jan; 21(1):103-8.
    View in: PubMed
    Score: 0.037
  22. Periostin, a novel biomarker of TH2-driven asthma. Curr Opin Pulm Med. 2014 Jan; 20(1):60-5.
    View in: PubMed
    Score: 0.035
  23. The efficacy and safety of the novel long-acting ?2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012 Jul; 142(1):119-127.
    View in: PubMed
    Score: 0.031
  24. Targeting IgE in asthma. Curr Opin Pulm Med. 2012 Jan; 18(1):1-5.
    View in: PubMed
    Score: 0.030
  25. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan; 106(1):91-101.
    View in: PubMed
    Score: 0.030
  26. Bronchodilator reversibility in COPD. Chest. 2011 Oct; 140(4):1055-1063.
    View in: PubMed
    Score: 0.030
  27. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. COPD. 2011 Aug; 8(4):293-9.
    View in: PubMed
    Score: 0.030
  28. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011 Jan 11; 12:6.
    View in: PubMed
    Score: 0.028
  29. Budesonide/formoterol combination in COPD: a US perspective. Int J Chron Obstruct Pulmon Dis. 2010 Oct 05; 5:357-66.
    View in: PubMed
    Score: 0.028
  30. Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J. 2010 Oct; 36(4):963-5.
    View in: PubMed
    Score: 0.028
  31. The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 Feb; 7(1):17-31.
    View in: PubMed
    Score: 0.027
  32. Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Curr Opin Pulm Med. 2010 Jan; 16(1):1-5.
    View in: PubMed
    Score: 0.026
  33. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm Pharmacol Ther. 2008; 21(3):540-50.
    View in: PubMed
    Score: 0.023
  34. The potential role of natural agents in treatment of airway inflammation. Ther Adv Respir Dis. 2007 Dec; 1(2):105-20.
    View in: PubMed
    Score: 0.023
  35. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. Clin Ther. 2007 Oct; 29(10):2121-33.
    View in: PubMed
    Score: 0.023
  36. Update on the pharmacologic therapy for chronic obstructive pulmonary disease. Clin Chest Med. 2007 Sep; 28(3):589-607, vi-vii.
    View in: PubMed
    Score: 0.023
  37. The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. Respir Med. 2007 May; 101(5):1007-14.
    View in: PubMed
    Score: 0.021
  38. Revisiting asthma control: how should it best be defined? Pulm Pharmacol Ther. 2007; 20(5):483-92.
    View in: PubMed
    Score: 0.021
  39. The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD. Int J Chron Obstruct Pulmon Dis. 2006; 1(4):345-54.
    View in: PubMed
    Score: 0.020
  40. Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025 Aug; 13(8):687-697.
    View in: PubMed
    Score: 0.019
  41. Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores. Respir Med. 2025 May; 241:108015.
    View in: PubMed
    Score: 0.019
  42. Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS. Chest. 2025 Jul; 168(1):56-66.
    View in: PubMed
    Score: 0.019
  43. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025 Mar; 13(3):234-243.
    View in: PubMed
    Score: 0.019
  44. Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). Respir Med. 2025 01; 236:107846.
    View in: PubMed
    Score: 0.018
  45. Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2372-2380.e5.
    View in: PubMed
    Score: 0.018
  46. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 May; 12(5):1215-1224.e3.
    View in: PubMed
    Score: 0.018
  47. Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024 05; 79(5):1134-1145.
    View in: PubMed
    Score: 0.017
  48. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003 Sep; 124(3):834-43.
    View in: PubMed
    Score: 0.017
  49. Clinic vs?Home Spirometry for Monitoring Lung Function in Patients With Asthma. Chest. 2023 11; 164(5):1087-1096.
    View in: PubMed
    Score: 0.017
  50. Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med. 2002 May 15; 165(10):1353-8.
    View in: PubMed
    Score: 0.016
  51. Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. J Allergy Clin Immunol Pract. 2022 07; 10(7):1835-1843.
    View in: PubMed
    Score: 0.015
  52. Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma. Chest. 2022 08; 162(2):297-308.
    View in: PubMed
    Score: 0.015
  53. New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology. Int J Chron Obstruct Pulmon Dis. 2018; 13:2805-2819.
    View in: PubMed
    Score: 0.012
  54. How does race/ethnicity influence pharmacological response to asthma therapies? Expert Opin Drug Metab Toxicol. 2018 Apr; 14(4):435-446.
    View in: PubMed
    Score: 0.012
  55. A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges. Int J Chron Obstruct Pulmon Dis. 2015; 10:725-38.
    View in: PubMed
    Score: 0.010
  56. Antifungals in severe asthma. Curr Opin Pulm Med. 2015 Jan; 21(1):48-54.
    View in: PubMed
    Score: 0.009
  57. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec; 146(6):1531-1542.
    View in: PubMed
    Score: 0.009
  58. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013 Dec; 132(6):1295-302.
    View in: PubMed
    Score: 0.009
  59. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May; 1(3):210-23.
    View in: PubMed
    Score: 0.008
  60. Comparative effectiveness of noninvasive ventilation vs invasive mechanical ventilation in chronic obstructive pulmonary disease patients with acute respiratory failure. J Hosp Med. 2013 Apr; 8(4):165-72.
    View in: PubMed
    Score: 0.008
  61. Age-related differences in asthma outcomes in the United States, 1988-2006. Ann Allergy Asthma Immunol. 2013 Apr; 110(4):240-6, 246.e1.
    View in: PubMed
    Score: 0.008
  62. Age-related differences in clinical outcomes for acute asthma in the United States, 2006-2008. J Allergy Clin Immunol. 2012 May; 129(5):1252-1258.e1.
    View in: PubMed
    Score: 0.008
  63. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol. 2011 Jul; 107(1):65-70.
    View in: PubMed
    Score: 0.007
  64. It's about time--directing our attention toward modifying the course of COPD. Respir Med. 2008 Jun; 102 Suppl 1:S37-48.
    View in: PubMed
    Score: 0.006
  65. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008 Feb; 5(1):25-34.
    View in: PubMed
    Score: 0.006
  66. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb; 29(2):261-78.
    View in: PubMed
    Score: 0.005
  67. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med. 2006 May; 24(3):259-67.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.